News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Guidelines for Treatment of Multiple Myeloma-Related Bone Disease Released

Jun 26, 2013
Leah Lawrence

The International Myeloma Working Group recently released new recommendations to aid physicians in the treatment of bone disease related to multiple myeloma.

The International Myeloma Working Group (IMWG) recently released a set of recommendations to aid physicians in the treatment of bone disease related to multiple myeloma. The guidelines incorporate new data from studies through August 2012 and update recommendations for the use of bisphosphonates, zoledronic acid, and other treatments.

A panel of experts in the field of multiple myeloma and myeloma-related bone disease worked to develop the guidelines and published them in the Journal of Clinical Oncology.

“Several novel data that were published during the last 5 years by the MRC-IX study group and others have changed the landscape of the management of myeloma-related bone disease and, thus, the IMWG should publish novel guidelines for the myeloma-treating physicians,” said Evangelos Terpos, MD, PhD, lead author on the guidelines and assistant professor of hematology at the University of Athens School of Medicine, Greece.

“The guidelines aim to help physicians to better manage myeloma patients with bone disease and also to help them prevent skeletal-related events that deteriorate the quality of life of myeloma patients, but also to prevent the side effects of the drugs used,” he told Cancer Network.

Among the recommendations detailed in the paper are several new guidelines discussing the appropriate patient population and choice of bisphosphonates. First, the panel recommended that bisphosphonates be considered in all patients with multiple myeloma receiving front-line anti-myeloma therapy regardless of the presence of osteolytic bone lesions on conventional therapy.

“However, it is unknown if bisphosphonates offer any advantage in patients with no bone disease assessed by low-dose whole body CT, MRI, or PET/CT,” Dr. Terpos said.

Second, the panel recommended that zoledronic acid be the preferred treatment over oral clodronate in newly diagnosed patients. This is recommended based on zoledronic acid’s potential anti-myeloma effects and survival benefits.

“Zoledronic acid is the only bisphosphonate shown to increase survival in the whole studied population of a prospective randomized trial,” the panel members wrote.

In addition, zoledronic acid was found to improve overall survival and reduce skeletal-related events compared with clodronate in patients who received treatment for more than 2 years. Therefore, the panel recommended that zoledronic acid be administered until disease progression in patients not in complete remission or a very good partial remission and further continued at relapse.

In contrast, no similar evidence was found for pamidronate; pamidronate should be continued in patients with active disease at the physician’s discretion.

“For patients in complete remission/very good partial remission, the optimal treatment duration of bisphosphonates is not clear; the panel agrees that bisphosphonates should be given for at least 12 months and up to 24 months, and then at the physician’s discretion,” Dr. Terpos said. “All previous guidelines suggested the 2-year duration of bisphosphonates in newly diagnosed myeloma patients.”

Finally, the panel recommended that balloon kyphoplasty should be considered for symptomatic vertebral compression fractures and is the procedure of choice to improve quality of life in patients with painful vertebral compression fractures. According to the panel, the role of vertebroplasty for myeloma patients is less clear as there is no randomized trial of vertebroplasty in myeloma patients.

Related Videos
Experts on multiple myeloma
Experts on multiple myeloma
Experts on multiple myeloma
For clinicians practicing in the community, constant communication and education from those in institutions may help to produce the best quality of care for patients with multiple myeloma.
Expert on MM
Experts on MM
Ashley E. Rosko, MD, specializes in multidisciplinary care for elderly patients with multiple myeloma, and how to make treatment most accessible to them.
At first relapse, novel therapies are offered to patients with multiple myeloma at The Ohio State University Comprehensive Cancer Center-The James.
Related Content

Inflammatory CD4/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology

May 23rd 2023

Oncology On-The-Go Podcast: Multiple Myeloma Outcome Disparities, Trial Access

April 12th 2023

Personalized Therapy Options Are on the Horizon in Multiple Myeloma

May 20th 2023

Between the Lines™ Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma

May 23rd 2022

Hispanic Population Has Worse Treatment Access/Outcomes in Multiple Myeloma

May 15th 2023

Momelotinib Use in the MOMENTUM Trial

May 15th 2023

Inflammatory CD4/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology

May 23rd 2023

Oncology On-The-Go Podcast: Multiple Myeloma Outcome Disparities, Trial Access

April 12th 2023

Personalized Therapy Options Are on the Horizon in Multiple Myeloma

May 20th 2023

Between the Lines™ Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma

May 23rd 2022

Hispanic Population Has Worse Treatment Access/Outcomes in Multiple Myeloma

May 15th 2023

Momelotinib Use in the MOMENTUM Trial

May 15th 2023

Inflammatory CD4/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology

May 23rd 2023

Oncology On-The-Go Podcast: Multiple Myeloma Outcome Disparities, Trial Access

April 12th 2023

Personalized Therapy Options Are on the Horizon in Multiple Myeloma

May 20th 2023

Between the Lines™ Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma

May 23rd 2022

Hispanic Population Has Worse Treatment Access/Outcomes in Multiple Myeloma

May 15th 2023

Momelotinib Use in the MOMENTUM Trial

May 15th 2023
Related Content

Inflammatory CD4/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology

Inflammatory CD4/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology

May 23rd 2023
Article

A recently published article highlights the use of CD4-positive/CD8-positive double-positive T cells as a predictive marker for graft-versus-host disease.


Krina Patel, MD, MSc, discusses research and initiatives that may help to mitigate disparities in patients with multiple myeloma including factors such as gender, race, and ethnicity.

Oncology On-The-Go Podcast: Multiple Myeloma Outcome Disparities, Trial Access

April 12th 2023
Podcast

Krina Patel, MD, MSc, discusses research and initiatives that may help to mitigate disparities in patients with multiple myeloma including factors such as gender, race, and ethnicity.


Personalized Therapy Options Are on the Horizon in Multiple Myeloma | Image Credit: © LASZLO - stock.adobe.com.

Personalized Therapy Options Are on the Horizon in Multiple Myeloma

May 20th 2023
Article

Ashley E. Rosko, MD, reviews unmet needs and treatment sequencing for patients with multiple myeloma.


Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.

Between the Lines™ Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma

May 23rd 2022
Podcast

Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.


Among those with multiple myeloma, Hispanic patients may experience worse outcomes such as in-hospital mortality vs other ethnic groups.

Hispanic Population Has Worse Treatment Access/Outcomes in Multiple Myeloma

May 15th 2023
Article

Among those with multiple myeloma, Hispanic patients may experience worse outcomes such as in-hospital mortality vs other ethnic groups.


Momelotinib Use in the MOMENTUM Trial

Momelotinib Use in the MOMENTUM Trial

May 15th 2023
Article

Lead study author Ruben Mesa, MD, discusses findings from the MOMENTUM trial assessing the use of momelotinib in the treatment of myelofibrosis.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.